Healthcare Industry News: Boston Scientific
News Release - May 15, 2012
Todd Campbell Appointed Vice President of Operations of ValveXchange, Inc.DENVER--(Healthcare Sales & Marketing Network)--ValveXchange is pleased to announce the appointment of Mr. Todd D. Campbell as Vice President of Operations.
Mr. Campbell has been Sr. Executive Director of Product Development at ValveXchange since 2011, and worked with the company on a consulting basis previously. His appointment as Vice President of Operations reflects the company’s continued growth toward commercialization of its novel 2-part heart valve technology.
During his 36-year career, Mr. Campbell has specialized in implantable medical devices, with an emphasis on prosthetic heart valves. He has been involved in the research, development, manufacturing and qualification of such devices for companies including Hancock Laboratories (now part of Medtronic), Edwards, Medtronic, St. Jude Medical, Sadra Medical (now part of Boston Scientific), and AorTx (now part of Hansen Medical).
As Vice President of Operations, Mr. Campbell is responsible for the facilities and resources necessary for ValveXchange to obtain the components and materials, process the tissue used in its bioprosthetic heart valves, and to build those valves in clean room conditions under exacting quality requirements. He will also help establish key vendor and other business relationships needed to move the company to commercialization of its heart valve products.
Mr. Blankenship said, “We are extremely pleased to have Todd lead these activities as we move into formal clinical trials and then to market launch. His experience in tissue processing and manufacturing medical implants is ideal for ValveXchange.”
The ValveXchange® technology was invented by company founder and noted heart valve scientist Dr. Ivan Vesely. Dr. Vesely said, “Todd has set up an outstanding clean room manufacturing facility. We are now fully integrated to build and ship product the day we get Approval.”
Having completed successful First-In-Man clinical studies in 2011, ValveXchange® will begin clinical trials in Europe in 2012, with regulatory approval for sale expected in 2013.
About ValveXchange, Inc.
ValveXchange, Inc. is focused on developing the “future of heart valve therapy.” The ValveXchange two-part architecture represents the first-of-its-kind "serviceable" bioprosthetic heart valve. By offering the capability to exchange worn-out leaflets, patients of all ages can enjoy a full, active lifestyle, avoiding a mechanical valve and its associated life-long anticoagulation therapy.
FORWARD-LOOKING STATEMENTS: This document includes statements which reflect management’s views, but which may not occur as expected, or at all.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.